180 related articles for article (PubMed ID: 33543397)
1. A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability.
Jimenez J; Washington MA; Resnick JL; Nischal KK; Fedorchak MV
Drug Deliv Transl Res; 2021 Oct; 11(5):2224-2238. PubMed ID: 33543397
[TBL] [Abstract][Full Text] [Related]
2. Ocular biodistribution of cysteamine delivered by a sustained release microsphere/thermoresponsive gel eyedrop.
Jimenez J; Resnick JL; Chaudhry AB; Gertsman I; Nischal KK; DiLeo MV
Int J Pharm; 2022 Aug; 624():121992. PubMed ID: 35809831
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
[TBL] [Abstract][Full Text] [Related]
4. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
[TBL] [Abstract][Full Text] [Related]
5. A Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis.
Csorba A; Katona G; Budai-Szűcs M; Balogh-Weiser D; Molnár P; Maka E; Kazsoki A; Vajna M; Zelkó R; Nagy ZZ; Balogh GT
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338900
[TBL] [Abstract][Full Text] [Related]
6. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
[TBL] [Abstract][Full Text] [Related]
7. [Ocular treatment of cystinosis with eye drop containing cysteamine].
Csorba A; Maka E; Szabó A; Kelen K; Reusz G; Nagy ZZ
Orv Hetil; 2022 May; 163(21):846-852. PubMed ID: 35598215
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.
Simpson JL; Nien CJ; Flynn KJ; Jester JV
Mol Vis; 2011; 17():2649-54. PubMed ID: 22065917
[TBL] [Abstract][Full Text] [Related]
9. [Cysteamine eyedrops for treatment of corneal cysteine deposits in infantile cystinosis].
Gräf M; Grote A; Wagner F
Klin Monbl Augenheilkd; 1992 Jul; 201(1):48-50. PubMed ID: 1513127
[TBL] [Abstract][Full Text] [Related]
10. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lenses.
Hsu KH; Fentzke RC; Chauhan A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):531-40. PubMed ID: 23665502
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.
Iwata F; Kuehl EM; Reed GF; McCain LM; Gahl WA; Kaiser-Kupfer MI
Mol Genet Metab; 1998 Aug; 64(4):237-42. PubMed ID: 9758713
[TBL] [Abstract][Full Text] [Related]
13. Cysteamine polysaccharide hydrogels: Study of extended ocular delivery and biopermanence time by PET imaging.
Luaces-Rodríguez A; Díaz-Tomé V; González-Barcia M; Silva-Rodríguez J; Herranz M; Gil-Martínez M; Rodríguez-Ares MT; García-Mazás C; Blanco-Mendez J; Lamas MJ; Otero-Espinar FJ; Fernández-Ferreiro A
Int J Pharm; 2017 Aug; 528(1-2):714-722. PubMed ID: 28634142
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of treatment with cysteamine eyedrops for cystinosis with confocal microscopy.
Tavares R; Coelho D; Macário MC; Torres A; Quadrado MJ; Murta J
Cornea; 2009 Sep; 28(8):938-40. PubMed ID: 19654516
[TBL] [Abstract][Full Text] [Related]
15. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
16. [Cysteamine ophthalmic hydrogel for the treatment of ocular cystinosis].
Fernández-Ferreiro A; Luaces-Rodríguez A; Díaz-Tomé V; Gil-Martínez M; Rodríguez Ares MT; Touriño Peralba R; Blanco-Méndez J; González-Barcia M; Otero-Espinar FJ; Lamas MJ
Farm Hosp; 2017 Nov; 41(6):678-687. PubMed ID: 29112493
[TBL] [Abstract][Full Text] [Related]
17. In vitro drug release and in vivo safety of vitamin E and cysteamine loaded contact lenses.
Dixon P; Fentzke RC; Bhattacharya A; Konar A; Hazra S; Chauhan A
Int J Pharm; 2018 Jun; 544(2):380-391. PubMed ID: 29217475
[TBL] [Abstract][Full Text] [Related]
18. NIH conference. Cystinosis: progress in a prototypic disease.
Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
[TBL] [Abstract][Full Text] [Related]
19. Effect of pH and penetration enhancers on cysteamine stability and trans-corneal transport.
Pescina S; Carra F; Padula C; Santi P; Nicoli S
Eur J Pharm Biopharm; 2016 Oct; 107():171-9. PubMed ID: 27395395
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of topical cysteamine in nephropathic cystinosis.
Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
